(Reuters) - AmeriPath, controlled by Welsh, Carson, Anderson and Stowe IX L.P., provides dermatopathology, anatomic pathology and esoteric testing and has annual revenue of more than $800 million.
The total deal value, including about $770 million in assumed debt, comes to $2 billion, the companies said.
Read more at Reuters.com Bonds News
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment